Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol

Exclusion Criteria

• •Known allergy to Vitamin D or calcium carbonate
• •Administration of vitamin D analogue or phosphate binders 3 months prior to study entry
• •History of hypercalcemia (corrected serum calcium \> 10.5 mg/dL) or hypophosphatemia (serum phosphate \< 2.5 mg/dL) 3 months prior to study entry
• •Patients with bone pathologies or diseases requiring vitamin D therapy that is unrelated to CKD-MBD
• •Administration of concurrent medication , diseases, or history of surgeries that may affect bone-mineral metabolism or alter bone status
• •Patients diagnosed with rapidly progressive glomerulonephritis(RPGN) or those in need of renal replacement therapy
• •Patients with obstructive bowel diseases, or severe gastrointestinal diseases
• •Patients with less than 2 years of life expectancy(ex. Malignancy diseases)